Skip to main content
NVCT
NASDAQ Life Sciences

Nuvectis Q3 10-Q: $140.7M Cash, $43.1M Nine-Month Loss After Haisco Charge

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$19.34
Mkt Cap
$631.336M
52W Low
$5.55
52W High
$29.275
52W Position info
248% above low
Off High info
34% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

NVCT has more than doubled off its 52-week low of $5.55.

Summary

Nuvectis reported a $43.1 million nine-month net loss, driven largely by the $20.0 million Haisco upfront payment expensed as R&D, and ended September with $140.7 million in cash after its July offering and ATM sales.


Key Events · Earnings and Guidance · NVCT

  • Q3 Net Loss Widens on Haisco Charge

    Nine-month net loss was $43.1 million versus $19.1 million a year earlier; Q3 alone lost $30.1 million versus $7.5 million.

  • Haisco Upfront Expensed as R&D

    The $20.0 million non-refundable upfront payment to Haisco was recorded as research and development expense, lifting nine-month R&D to $36.2 million from $13.1 million.

  • Cash Position After July Raise

    Cash and equivalents were $140.7 million at September 30, 2026, up from $31.6 million at year-end 2025, after the $115.0 million July public offering and $39.7 million of ATM proceeds.

  • Share Count Rises on Offerings

    Shares outstanding reached 34,388,908 as of October 30, 2026, versus 25,676,798 at December 31, 2025, reflecting the July offering, ATM sales and restricted stock awards.


Analysis · NVCT · Life Sciences

The headline numbers were already out this morning, but the 10-Q shows what drove them. A $20.0 million Haisco upfront payment was expensed immediately as acquired IPR&D, pushing R&D to $36.2 million for the nine months and widening the net loss to $43.1 million from $19.1 million. Against that, the July offering and ATM sales left $140.7 million of cash, which management estimates funds at least 12 months of operations. The share count rose to 34,388,908 from 25,676,798 at year-end 2025, so the cash came at the cost of meaningful dilution. No going-concern language and no new financing terms.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NVCT was trading at $19.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $631.3M. The 52-week trading range was $5.55 to $29.28. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NVCT - Latest Insights

NVCT
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $19.42
Real-time Price: $20.40 info
Change: +$0.980 (+5%) info
Market Cap: $682.276M info
NVCT
Nov 04, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $19.34
Real-time Price: $20.40 info
Change: +$1.06 (+5%) info
Market Cap: $682.276M info
NVCT
Oct 26, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $20.05
Real-time Price: $20.40 info
Change: +$0.350 (+2%) info
Market Cap: $682.276M info
NVCT
Sep 24, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $21.70
Real-time Price: $20.40 info
Change: -$1.30 (-6%) info
Market Cap: $682.276M info
NVCT
Aug 21, 2026, 4:37 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $23.56
Real-time Price: $20.40 info
Change: -$3.16 (-13%) info
Market Cap: $682.276M info